Prosecution Insights
Prosecution Insights
60 pending office actions • 40 art units • 57 examiners • 0 of 60 (0%) have an AI response strategy ready • 78 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 60 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 60 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §103 only | 39 (65%) |
| §102 only | 3 (5%) |
| §112 only | 6 (10%) |
| No statute on record | 11 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 2 | 59.8% | +18.5% |
| BELL, SARA ELIZABETH | 2 | 73.5% | +39.9% |
| GODDARD, LAURA B | 2 | 50.7% | +14.6% |
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| RODRIGUEZ, RAYNA B | 1 | 32.4% | +21.6% |
| GAVIN, KRISTIN ELIZABETH | 1 | 15.1% | +16.6% |
| CWERN, JONATHAN | 1 | 50.7% | +35.3% |
| BURSUM, KIMBERLY SUZANNE | 1 | 32.9% | +10.5% |
| KONOPKA, CATHERINE ANNE | 1 | 58.8% | +63.7% |
| BOUCHELLE, LAURA A | 1 | 80.2% | +10.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18743859 | METHOD AND APPARATUS FOR USING OMALIZUMAB | BOUCHELLE, LAURA A | 5d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 396d overdue |
| 18859952 | DRUG PRODUCTION METHOD | GAVIN, KRISTIN ELIZABETH | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | KONOPKA, CATHERINE ANNE | 78d overdue |
| 17999799 | BELVARAFENIB FOR USE IN CANCER TREATMENT | BELL, SARA ELIZABETH | 78d overdue |
| 19285781 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | WEN, SHARON X | 56d overdue |
| 18364185 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | ALLEN, MARIANNE P | 43d overdue |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | ALLEN, MARIANNE P | 26d overdue |
| 18883384 | DEEP CONVOLUTIONAL NEURAL NETWORKS FOR TUMOR SEGMENTATION WITH POSITRON EMISSION TOMOGRAPHY | CWERN, JONATHAN | 24d overdue |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GODDARD, LAURA B | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 4 |
| 1641 | 3 |
| 1653 | 3 |
| 1643 | 3 |
| 1647 | 3 |
| 1644 | 3 |
| 1646 | 3 |
| 1628 | 2 |
| 1678 | 2 |
| 1758 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19285781 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | WEN, SHARON X | 1641 | Other | Non-Final OA | 56d overdue | Pending | Jul 30, 2025 |
| 19210611 | CDK INHIBITORS | RODRIGUEZ, RAYNA B | 1628 | §112 | Non-Final OA | 61d | Pending | May 16, 2025 |
| 18859952 | DRUG PRODUCTION METHOD | GAVIN, KRISTIN ELIZABETH | 3624 | §103 | Final Rejection | 40d | Pending | Oct 24, 2024 |
| 18883384 | DEEP CONVOLUTIONAL NEURAL NETWORKS FOR TUMOR SEGMENTATION WITH POSITRON EMISSION TOMOGRAPHY | CWERN, JONATHAN | 3797 | §103 | Final Rejection | 24d overdue | Pending | Sep 12, 2024 |
| 18828915 | PHARMACEUTICAL ASSET TRACKING | BURSUM, KIMBERLY SUZANNE | 3627 | §103 | Non-Final OA | 15d | Pending | Sep 09, 2024 |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | KONOPKA, CATHERINE ANNE | 1635 | Other | Final Rejection | 78d overdue | Pending | Jun 24, 2024 |
| 18743859 | METHOD AND APPARATUS FOR USING OMALIZUMAB | BOUCHELLE, LAURA A | 3783 | §103 | Final Rejection | 5d overdue | Pending | Jun 14, 2024 |
| 18669218 | SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 22d overdue | Pending | May 20, 2024 |
| 18664892 | DEEP LEARNING FOR MODELING DISEASE PROGRESSION | JAMES, DOMINIQUE NICOLE | 2666 | §103 | Non-Final OA | 35d | Pending | May 15, 2024 |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 2676 | §103 | Non-Final OA | 31d overdue | Pending | Apr 04, 2024 |
| 18536174 | HIERARCHICAL WORKFLOW FOR GENERATING ANNOTATED TRAINING DATA FOR MACHINE LEARNING ENABLED IMAGE SEGMENTATION | TSAI, TSUNG YIN | 2656 | §103 | Non-Final OA | 107d overdue | Pending | Dec 11, 2023 |
| 18526572 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | AULAKH, CHARANJIT | 1621 | §102 | Non-Final OA | 47d | Pending | Dec 01, 2023 |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 1691 | §103 | Non-Final OA | 91d overdue | Pending | Nov 29, 2023 |
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | SCHMITT, MICHAEL J | 1629 | Other | Non-Final OA | 55d | Pending | Nov 21, 2023 |
| 18491555 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103 | Non-Final OA | 50d overdue | Pending | Oct 20, 2023 |
| 18482237 | TREATMENT OUTCOME PREDICTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING BASELINE CHARACTERISTICS | WINDSOR, COURTNEY J | 2661 | §103 | Final Rejection | 31d overdue | Pending | Oct 06, 2023 |
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | 4d overdue | Pending | Sep 11, 2023 |
| 18463585 | ATTENTION-BASED MULTIPLE INSTANCE LEARNING FOR WHOLE SLIDE IMAGES | TRAN, DUY ANH | 2674 | §102 | Final Rejection | 13d | Pending | Sep 08, 2023 |
| 18449807 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND IPATASERTIB | CHAO, ALLEN | 1622 | Other | Non-Final OA | 66d overdue | Pending | Aug 15, 2023 |
| 18449800 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND GDC-0077 | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Non-Final OA | 16d overdue | Pending | Aug 15, 2023 |
| 18364185 | ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 43d overdue | Pending | Aug 02, 2023 |
| 18357772 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | WALLACE, JOHN R | 2682 | §103 | Non-Final OA | 5d overdue | Pending | Jul 24, 2023 |
| 18349015 | Methods and Systems for Determining Kinetic Parameters | GABEL, GAILENE | 1678 | §103 | Non-Final OA | 28d | Pending | Jul 07, 2023 |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 111d overdue | Pending | Jun 15, 2023 |
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 28d | Pending | Jun 14, 2023 |
| 18206853 | METHODS FOR DETERMINING THE RELATIVE DISTRIBUTION OF GLUCURONIDATION, IDURONIDATION, AND GALACTURONIDATION OF POLYPEPTIDES | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Non-Final OA | 34d | Pending | Jun 07, 2023 |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | SITTON, JEHANNE SOUAYA | 1682 | §103 | Non-Final OA | 52d overdue | Pending | Jun 06, 2023 |
| 18204281 | INDUCTIVE HEAT STERILIZING SYSTEMS, DEVICES, AND METHODS | LEE, AHAM NMN | 1758 | §103 | Non-Final OA | 14d | Pending | May 31, 2023 |
| 18323240 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | BELL, SARA ELIZABETH | 1625 | Other | Non-Final OA | 34d | Pending | May 24, 2023 |
| 18321199 | CONTAINED SINGLE-USE POWDER INDUCTION SYSTEM AND METHOD OF USE | BHATIA, ANSHU | 1774 | §103 | Non-Final OA | 27d | Pending | May 22, 2023 |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 1711 | §103 | Non-Final OA | 58d overdue | Pending | May 10, 2023 |
| 18297546 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JARRELL, NOBLE E | 1699 | §112 | Final Rejection | 66d overdue | Pending | Apr 07, 2023 |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | ALLEN, MARIANNE P | 1647 | Other | Non-Final OA | 26d overdue | Pending | Apr 04, 2023 |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | BRISTOL, LYNN ANNE | 1643 | §103 | Non-Final OA | 10d overdue | Pending | Mar 21, 2023 |
| 18043568 | HIGH THROUGHPUT, FLUORESCENCE-BASED ESTERASE ACTIVITY ASSAY FOR ASSESSING POLYSORBATE DEGRADATION RISK DURING BIOPHARMACEUTICAL DEVELOPMENT | XU, QING | 1656 | §103 | Non-Final OA | 84d | Pending | Feb 28, 2023 |
| 18173002 | ASSAYS AND REAGENTS FOR CHARACTERIZATION OF MHCI PEPTIDE BINDING | LUSI, ELLIS FOLLETT | 1677 | §103 | Non-Final OA | 21d | Pending | Feb 22, 2023 |
| 18163819 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | CASH, KAILEY ELIZABETH | 1683 | §103 | Non-Final OA | 22d | Pending | Feb 02, 2023 |
| 18156744 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | VAN DRUFF, SYDNEY | 1643 | Other | Non-Final OA | 53d overdue | Pending | Jan 19, 2023 |
| 18004550 | Anti-Notch2 Antibodies and Methods of Use | HADDAD, MAHER M | 1641 | Other | Final Rejection | 49d overdue | Pending | Jan 06, 2023 |
| 17999799 | BELVARAFENIB FOR USE IN CANCER TREATMENT | BELL, SARA ELIZABETH | 1625 | Other | Non-Final OA | 78d overdue | Pending | Nov 23, 2022 |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GODDARD, LAURA B | 1642 | §103 | Non-Final OA | 10d overdue | Pending | Oct 24, 2022 |
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | 12d | Pending | Oct 14, 2022 |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | 127d overdue | Pending | Oct 12, 2022 |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | 87d overdue | Pending | Aug 26, 2022 |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 37d overdue | Pending | Jun 16, 2022 |
| 17806252 | INHALER DEVICES, MEDICATION FORMULATIONS USED THEREWITH AND METHODS OF MANUFACTURE | RUDDIE, ELLIOT S | 3785 | §103 | Non-Final OA | 44d overdue | Pending | Jun 09, 2022 |
| 17629327 | DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA | MINCHELLA, KAITLYN L | 1685 | §103 | Final Rejection | 88d overdue | Pending | Jan 21, 2022 |
| 17513710 | PURIFICATION PLATFORMS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED HYDROLYTIC ENZYME ACTIVITY RATE | SUNSHINE, HANNAH LOUISE | 1647 | §103 | Non-Final OA | 7d | Pending | Oct 28, 2021 |
| 17503122 | ANTIBODY POTENCY ASSAY | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Non-Final OA | 1d overdue | Pending | Oct 15, 2021 |
| 17490877 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | NGUYEN, NGOC-ANH THI | 1615 | §103 | Non-Final OA | 53d | Pending | Sep 30, 2021 |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | 4d overdue | Pending | Sep 13, 2021 |
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 1687 | §101 | Non-Final OA | 396d overdue | Pending | Jul 16, 2021 |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 1642 | §102 | Final Rejection | 84d overdue | Pending | Jun 18, 2021 |
| 17343543 | MODIFIED ANTIBODY FCS AND METHODS OF USE | GUSTILO, ESTELLA M | 1646 | §103 | Non-Final OA | 15d overdue | Pending | Jun 09, 2021 |
| 17229746 | COPPER LOSS MITIGATION | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | 9d | Pending | Apr 13, 2021 |
| 17275609 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | LEE, CHIHYI NMN | 1628 | §103 | Final Rejection | 27d | Pending | Mar 11, 2021 |
| 17249457 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | KENYON, JOHN S | 1625 | §112 | Final Rejection | 98d overdue | Pending | Mar 02, 2021 |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | AFREMOVA, VERA | 1653 | §103 | Final Rejection | 49d overdue | Pending | Feb 10, 2021 |
| 16221369 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | HALVORSON, MARK | 1646 | §103 | Non-Final OA | 80d overdue | Pending | Dec 14, 2018 |
| 16185369 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 15d | Pending | Nov 09, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial